Equillium, Inc. (NASDAQ:EQ) Stock Has Consensus Price Target of $7.57

Equillium, Inc. (NASDAQ:EQ) has received an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.57.

Several analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Equillium in a research report on Monday, July 13th. They set an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a report on Monday, September 21st. Wall Street Zen downgraded shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Roth Capital reissued a “buy” rating and set a $12.00 price objective on shares of Equillium in a report on Friday, September 4th. Finally, Clear Str raised Equillium to a “strong-buy” rating in a research report on Tuesday, July 21st.

Equillium Stock Performance

Shares of Equillium stock opened at $1.41 on Tuesday. The company has a market capitalization of $89.41 million, a PE ratio of -7.05 and a beta of 1.93. The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.32. Equillium has a one year low of $0.76 and a one year high of $3.54.

Equillium (NASDAQ:EQ) last posted its earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, equities analysts predict that Equillium will post -0.21 earnings per share for the current fiscal year.

Institutional Trading of Equillium

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jupiter Topco LLC acquired a new stake in Equillium during the second quarter valued at $20,685,000. ADAR1 Capital Management LLC acquired a new stake in shares of Equillium during the 2nd quarter valued at about $12,027,000. Eversept Partners LP acquired a new stake in shares of Equillium during the 1st quarter valued at about $2,998,000. Affinity Asset Advisors LLC purchased a new position in Equillium during the first quarter worth approximately $2,453,000. Finally, Janus Henderson Group PLC grew its holdings in Equillium by 10.8% in the first quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company’s stock valued at $12,957,000 after purchasing an additional 632,359 shares during the period. 27.05% of the stock is currently owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s research is based on modulating immune pathways involved in T-cell activation, inflammation and tissue damage.

Its lead investigational product is itolizumab, an anti-CD6 monoclonal antibody designed to regulate pathogenic T-cell activity. Equillium has evaluated itolizumab in immune-mediated conditions, including acute graft-versus-host disease and other inflammatory disorders.